Medication info
Amoratanal Tablet 5/160/5 mg

Amoratanal Tablet 5/160/5 mg

Prescription medicationTabletOral
Ingredient · strength
Amlodipine Besylate›6.94mg / 1 tabletValsartan›160mg / 1 tabletRosuvastatin Calcium›5.2mg / 1 tablet
Manufacturer / importer
CMG Pharmaceutical Co., Ltd.
Appearance
Pale yellow-pink oval film-coated tablet
Packaging
30 tablets/bottle, 100 tablets/bottle
Approval status
Active

MFDS item code 202108063 · Approved 2021.12.21 · Insurance code 648604370

Summary

Main use
Improves hypertension and dyslipidemia, and inhibits the progression of atherosclerosis and the risk of cardiovascular disease
Who takes it
Adults
Adult dose
Take 1 tablet once daily with water. If possible, it is recommended that this medicine be taken at the same time every day (e.g., before breakfast). This medicine is for adults only. The dose should be individualized for each patient based on the efficacy and tolerability of the amlodipine/valsartan combination and rosuvastatin. For patients taking an amlodipine/valsartan combination and rosuvastatin as separate medicines, they may switch to this medicine (a combination product containing the same amounts of each active ingredient) for convenience. ▷ Amlodipine/valsartan combination Before administering the amlodipine/valsartan combination, it is recommended that the dose be adjusted using the individual components (amlodipine or valsartan). However, if blood pressure is not adequately controlled with monotherapy using either component, switching directly to the amlodipine/valsartan combination may be considered, as follows. ㆍ5/80 mg: For patients whose blood pressure is not adequately controlled with amlodipine 5 mg or valsartan 80 mg monotherapy. ㆍ5/160 mg: For patients whose blood pressure is not adequately controlled with amlodipine 5 mg or valsartan 160 mg monotherapy. ㆍ10/160 mg: For patients whose blood pressure is not adequately controlled with amlodipine 10 mg or valsartan 160 mg monotherapy, or with 5/160 mg. Patients with renal impairment: No dose adjustment is necessary in patients with mild or moderate renal impairment (creatinine clearance 10mL/min or more); however, the amlodipine/valsartan combination should not be administered to patients with severe renal impairment (creatinine clearance less than 10mL/min) or patients on dialysis. In patients with moderate renal impairment, monitoring of potassium levels and creatinine is recommended. Patients with hepatic impairment: In patients with mild or moderate hepatic impairment, the daily dose of valsartan should not exceed 80 mg. The amlodipine/valsartan combination should not be administered to patients with severe hepatic impairment, biliary cirrhosis, biliary obstruction, or cholestasis. Patients aged 65 years or older: Caution should be exercised when increasing the dose. ▷ Rosuvastatin 1. Primary hypercholesterolemia (including heterozygous familial hypercholesterolemia, type IIa), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment with rosuvastatin and continue it throughout the treatment period. Rosuvastatin may be taken at any time of day, with or without food. The initial dose is 5 mg once daily. If a greater reduction in LDL cholesterol is needed, the dose may be adjusted to a maintenance dose. The maintenance dose is 10 mg once daily, which is sufficient to control the condition in most patients. The maintenance dose should be adjusted appropriately at intervals of 4 weeks or longer according to LDL cholesterol levels, treatment goals, and the patient's response; the dose may be increased to a maximum of 20 mg daily. 2. Older patients: No dose adjustment is necessary. 3. Patients with renal impairment: No dose adjustment is necessary in patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Particular caution should be exercised when administering rosuvastatin 20 mg to patients with moderate renal impairment. 4. Patients with hepatic impairment: No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function testing should be considered in these patients. There is no experience with administration to patients with a Child-Pugh score greater than 9. Do not administer rosuvastatin to patients with active liver disease. 5. Race: Because systemic exposure to this medicine is increased in Asian patients, the recommended initial dose is 5 mg. Administration of the 40 mg dose is contraindicated. 6. Patients predisposed to myopathy: The recommended initial dose for patients predisposed to myopathy is 5 mg. Administration of the 40 mg dose of rosuvastatin is contraindicated in some of these patients.

Ingredients

Manufacturer
CMG Pharmaceutical Co., Ltd.

Efficacy & effects

Improves hypertension and dyslipidemia, and inhibits the progression of atherosclerosis and the risk of cardiovascular disease

  • Essential hypertension
  • primary hypercholesterolemia
  • heterozygous familial hypercholesterolemia
  • combined dyslipidemia
  • homozygous familial hypercholesterolemia
  • hypercholesterolemia
  • primary dysbetalipoproteinemia
  • coronary artery disease risk factors
  • hypertension
  • low HDL cholesterol levels
  • smoking
  • family history of early coronary artery disease
View approved original text

This medication is used in patients with essential hypertension who have difficulty controlling blood pressure with monotherapy and combines amlodipine and valsartan. Additionally, rosuvastatin is administered as an adjunct in patients with hypercholesterolemia and dyslipidemia when diet alone does not suffice, to lower blood cholesterol levels and delay the progression of atherosclerosis. In high-risk cardiovascular disease patients, it also reduces the risks of myocardial infarction, stroke, and vascular revascularization procedures. Therefore, this medication is used to manage hypertension and dyslipidemia together and improve cardiovascular health.

How to take

Adult dose

Take 1 tablet once daily with water. If possible, it is recommended that this medicine be taken at the same time every day (e.g., before breakfast). This medicine is for adults only. The dose should be individualized for each patient based on the efficacy and tolerability of the amlodipine/valsartan combination and rosuvastatin. For patients taking an amlodipine/valsartan combination and rosuvastatin as separate medicines, they may switch to this medicine (a combination product containing the same amounts of each active ingredient) for convenience. ▷ Amlodipine/valsartan combination Before administering the amlodipine/valsartan combination, it is recommended that the dose be adjusted using the individual components (amlodipine or valsartan). However, if blood pressure is not adequately controlled with monotherapy using either component, switching directly to the amlodipine/valsartan combination may be considered, as follows. ㆍ5/80 mg: For patients whose blood pressure is not adequately controlled with amlodipine 5 mg or valsartan 80 mg monotherapy. ㆍ5/160 mg: For patients whose blood pressure is not adequately controlled with amlodipine 5 mg or valsartan 160 mg monotherapy. ㆍ10/160 mg: For patients whose blood pressure is not adequately controlled with amlodipine 10 mg or valsartan 160 mg monotherapy, or with 5/160 mg. Patients with renal impairment: No dose adjustment is necessary in patients with mild or moderate renal impairment (creatinine clearance 10mL/min or more); however, the amlodipine/valsartan combination should not be administered to patients with severe renal impairment (creatinine clearance less than 10mL/min) or patients on dialysis. In patients with moderate renal impairment, monitoring of potassium levels and creatinine is recommended. Patients with hepatic impairment: In patients with mild or moderate hepatic impairment, the daily dose of valsartan should not exceed 80 mg. The amlodipine/valsartan combination should not be administered to patients with severe hepatic impairment, biliary cirrhosis, biliary obstruction, or cholestasis. Patients aged 65 years or older: Caution should be exercised when increasing the dose. ▷ Rosuvastatin 1. Primary hypercholesterolemia (including heterozygous familial hypercholesterolemia, type IIa), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment with rosuvastatin and continue it throughout the treatment period. Rosuvastatin may be taken at any time of day, with or without food. The initial dose is 5 mg once daily. If a greater reduction in LDL cholesterol is needed, the dose may be adjusted to a maintenance dose. The maintenance dose is 10 mg once daily, which is sufficient to control the condition in most patients. The maintenance dose should be adjusted appropriately at intervals of 4 weeks or longer according to LDL cholesterol levels, treatment goals, and the patient's response; the dose may be increased to a maximum of 20 mg daily. 2. Older patients: No dose adjustment is necessary. 3. Patients with renal impairment: No dose adjustment is necessary in patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Particular caution should be exercised when administering rosuvastatin 20 mg to patients with moderate renal impairment. 4. Patients with hepatic impairment: No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function testing should be considered in these patients. There is no experience with administration to patients with a Child-Pugh score greater than 9. Do not administer rosuvastatin to patients with active liver disease. 5. Race: Because systemic exposure to this medicine is increased in Asian patients, the recommended initial dose is 5 mg. Administration of the 40 mg dose is contraindicated. 6. Patients predisposed to myopathy: The recommended initial dose for patients predisposed to myopathy is 5 mg. Administration of the 40 mg dose of rosuvastatin is contraindicated in some of these patients.

Precautions

This medication may cause serious harm to the fetus and newborn if taken during pregnancy, especially in the second and third trimesters; therefore, it should be discontinued immediately upon confirmation of pregnancy. Patients with hypersensitivity to any components of this medication, severe hepatic impairment, biliary obstruction, or severe renal impairment should not use it. Caution is advised in patients with diabetes, reduced renal function, a history of angioedema, severe cardiac valvular disease, etc. Particularly in patients who are sodium- or fluid-depleted, hypotension may occur; therefore, status should be carefully checked before administration, and blood pressure and symptoms should be closely monitored during administration. Patients with high potassium levels should exercise caution when using potassium supplements or potassium-sparing diuretics and should have potassium levels frequently monitored. The safety of this medication has not been established in kidney transplant patients, thus caution is required for its use. If angioedema occurs, administration should be discontinued immediately, and it should not be re-administered. In patients with heart failure or following myocardial infarction, there is a possibility of worsening renal function or hypotension, necessitating regular monitoring of blood pressure and renal function. In patients with acute myocardial infarction or aortic stenosis, caution should be taken as the medication may worsen angina or cardiac symptoms. Some components of this medication may affect liver function, so dosage adjustment may be required for patients with poor liver function. Rosuvastatin can cause muscle pain, myopathy, and, rarely, rhabdomyolysis; hence, if muscle pain or weakness occurs, the doctor should be notified immediately. Dizziness or fatigue may occur when driving or operating machinery during the treatment, so caution is warranted. This medication can interact with various drugs, so inform the doctor or pharmacist of any other medications being taken. Women who are pregnant or breastfeeding should not take this medication, and effective contraception should be used if planning pregnancy. Elderly patients should start at a lower dosage and gradually increase to avoid excessive blood pressure reduction. In case of overdose, severe hypotension, shock, and heart failure may occur, requiring immediate emergency treatment.

Side effects

  • Peripheral edema
  • heat sensation
  • increased ALT
  • increased AST
  • increased serum creatinine
  • flank pain
  • neck pain
  • dizziness
  • sensory loss
  • pharyngitis
Show 164 more
  • rash
  • nasopharyngitis
  • influenza
  • hypersensitivity
  • visual impairment
  • anxiety
  • headache
  • drowsiness
  • orthostatic dizziness
  • sensory abnormalities
  • vertigo
  • tinnitus
  • tachycardia
  • palpitations
  • syncope
  • orthostatic hypotension
  • hypotension
  • cough
  • pharyngeal and laryngeal pain
  • diarrhea
  • nausea
  • abdominal pain
  • constipation
  • dry mouth
  • erythema
  • hyperhidrosis
  • rash
  • itching
  • joint swelling
  • low back pain
  • arthritis
  • muscle cramps
  • lethargy
  • polyuria
  • diabetes
  • erectile dysfunction
  • edema
  • local edema
  • facial edema
  • fatigue
  • flushing
  • weakness
  • facial flushing
  • chest pain
  • pain
  • nocturia
  • chest discomfort
  • abdominal discomfort
  • gastroesophageal reflux disease
  • hypercholesterolemia
  • hypoglycemia
  • urticaria
  • thrombocytopenia
  • leukopenia
  • allergic reaction
  • hyperglycemia
  • insomnia
  • mood changes
  • tremors
  • taste disturbance
  • peripheral neuropathy
  • hypertonia
  • arrhythmia
  • bradycardia
  • atrial fibrillation
  • ventricular tachycardia
  • vasculitis
  • dyspnea
  • rhinitis
  • vomiting
  • dyspepsia
  • pancreatitis
  • gastritis
  • gingival hyperplasia
  • hepatitis
  • jaundice
  • alopecia
  • purpura
  • skin depigmentation
  • photosensitivity reaction
  • angioedema
  • erythema multiforme
  • Stevens-Johnson syndrome
  • myalgia
  • voiding dysfunction
  • gynecomastia
  • malaise
  • weight loss
  • weight gain
  • decreased hemoglobin
  • decreased hematocrit
  • neutropenia
  • serum sickness
  • increased serum potassium
  • vasculitis
  • bullous dermatitis
  • renal failure
  • kidney damage
  • insomnia
  • decreased libido
  • pharyngitis
  • rhinitis
  • sinusitis
  • upper respiratory infection
  • viral infection
  • intestinal vascular edema
  • polyneuropathy
  • amnesia
  • peripheral neuropathy
  • thrombocytopenia
  • lupus-like syndrome
  • muscle rupture
  • immune-mediated necrotizing myopathy
  • hematuria
  • depression
  • sleep disorders
  • interstitial lung disease
  • fatal and non-fatal liver failure
  • post-marketing cognitive impairment
  • severe muscle weakness
  • ocular myasthenia
  • increased CK
  • constipation
  • oral bleeding
  • vomiting
  • insulin-dependent diabetes mellitus
  • diabetes complications
  • leg fractures
  • spinal fractures
  • fractures
  • skin tumors
  • second-degree AV block
  • vestibular neuritis
  • retinal detachment
  • unspecified skin tumor-like conditions
  • herpes zoster
  • intervertebral disc herniation
  • laceration
  • pruritus
  • rash
  • urticaria
  • myopathy
  • rhabdomyolysis
  • weakness
  • headache
  • dizziness
  • constipation
  • nausea
  • abdominal pain
  • pancreatitis
  • rash
  • arthralgia
  • skeletal pain
  • rhabdomyolysis
  • gingival hyperplasia
  • gastritis
  • nervous hyperactivity
  • sensory loss
  • Stevens-Johnson syndrome
  • angioedema
  • increased serum creatinine
  • acute kidney failure
  • oliguria
  • increased serum creatinine

Not everyone experiences these, and they can vary from person to person.

Storage

This medication may be sensitive to air or moisture; therefore, it should be stored in a tightly sealed container. The storage temperature should be maintained between 1 and 30 degrees Celsius to ensure the prolonged efficacy and safety of the medication.

Appearance and packaging

Appearance

Pale yellow-pink oval film-coated tablet

Package unit

30 tablets/bottle, 100 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.